iQur Leads Major European Project to Develop a Universal Influenza Virus Vaccine - - BioPharm International

ADVERTISEMENT

iQur Leads Major European Project to Develop a Universal Influenza Virus Vaccine



iQur, a UK biotechnology company, announced that it has been granted €5 million ($6.6 million) by the European Union Framework 7 fund to develop a universal influenza vaccine based on its proprietary tandem core technology.

iQur will lead a consortium of world-leading scientists from six sites across Europe, which have the complimentary skills and experience to discover and develop a novel flu vaccine. iQur’s technology will enable the design of a vaccine for influenza with the potential to confer long-term protection, removing the need for annual vaccination, the company reports. In addition, iQur’s vaccine can be made using recombinant protein technology and should be more effective and cheaper to manufacture than conventional vaccines, the company says.

The consortium partners include Leeds University and University College London from the UK, CRP Santé from Luxemburg, the Latvijas Medicinal Centre from Latvia, 3P Pharmaceuticals and Institut Catala de la Salut, both from Spain. The consortium will develop an optimal vaccine using preclinical models, manufacture the product to GMP and finally carry out a Phase I clinical trial. It is anticipated that the project will reach completion in 2017.

Source: iQur

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here